1. Home
  2. BODI vs EQ Comparison

BODI vs EQ Comparison

Compare BODI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Beachbody Company Inc.

BODI

The Beachbody Company Inc.

HOLD

Current Price

$11.00

Market Cap

56.8M

Sector

Industrials

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.35

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BODI
EQ
Founded
1998
2017
Country
United States
United States
Employees
355
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.8M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BODI
EQ
Price
$11.00
$2.35
Analyst Decision
Buy
Hold
Analyst Count
2
1
Target Price
$11.00
$1.00
AVG Volume (30 Days)
29.6K
342.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.47
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$25.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.89
52 Week Low
$3.38
$0.29
52 Week High
$12.66
$2.35

Technical Indicators

Market Signals
Indicator
BODI
EQ
Relative Strength Index (RSI) 63.68 75.24
Support Level $10.18 $1.22
Resistance Level $12.66 N/A
Average True Range (ATR) 0.85 0.19
MACD 0.42 0.03
Stochastic Oscillator 85.08 89.77

Price Performance

Historical Comparison
BODI
EQ

About BODI The Beachbody Company Inc.

The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: